88 related articles for article (PubMed ID: 21488920)
1. Rabeprazole extended-release 50 mg compared with esomeprazole 40 mg and rabeprazole delayed release 20 mg.
Yuan Y; Hunt RH
Aliment Pharmacol Ther; 2011 May; 33(10):1177-9; author reply 1179-80. PubMed ID: 21488920
[No Abstract] [Full Text] [Related]
2. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.
Morelli G; Chen H; Rossiter G; Rege B; Lu Y
Aliment Pharmacol Ther; 2011 Apr; 33(7):845-54. PubMed ID: 21272047
[TBL] [Abstract][Full Text] [Related]
3. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.
Wilder-Smith CH; Röhss K; Nilsson-Pieschl C; Junghard O; Nyman L
Digestion; 2003; 68(4):184-8. PubMed ID: 14691345
[TBL] [Abstract][Full Text] [Related]
4. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.
Eggleston A; Katelaris PH; Nandurkar S; Thorpe P; Holtmann G;
Aliment Pharmacol Ther; 2009 May; 29(9):967-78. PubMed ID: 19210493
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection.
McNicholl AG; Linares PM; Nyssen OP; Calvet X; Gisbert JP
Aliment Pharmacol Ther; 2012 Sep; 36(5):414-25. PubMed ID: 22803691
[TBL] [Abstract][Full Text] [Related]
7. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
Li ZS; Zhan XB; Xu GM; Cheng NN; Liao Z
J Gastroenterol Hepatol; 2007 Jun; 22(6):815-20. PubMed ID: 17565634
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
Laine L; Katz PO; Johnson DA; Ibegbu I; Goldstein MJ; Chou C; Rossiter G; Lu Y
Aliment Pharmacol Ther; 2011 Jan; 33(2):203-12. PubMed ID: 21114792
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
[TBL] [Abstract][Full Text] [Related]
10. Rabeprazole-induced acute cholestatic liver injury.
Aktaş B; Başar Ö; Altinbaş A; Ekiz F; Yüksel O
Turk J Gastroenterol; 2012 Jun; 23(3):309-10. PubMed ID: 22798130
[No Abstract] [Full Text] [Related]
11. Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials.
Edwards SJ; Lind T; Lundell L; DAS R
Aliment Pharmacol Ther; 2009 Sep; 30(6):547-56. PubMed ID: 19558609
[TBL] [Abstract][Full Text] [Related]
12. [All proton pump inhibitors are equally efficacious in standard dosages].
Hellström PM; Vitols S
Lakartidningen; 2003 Jun; 100(25):2212-6. PubMed ID: 12872509
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
14. In vitro release profile of anti-ulcer drug rabeprazole from biocompatible psyllium-PVA hydrogels.
Singh B; Lal H; Pal L; Sharma V
J Mater Sci Mater Med; 2012 Apr; 23(4):1021-32. PubMed ID: 22367108
[TBL] [Abstract][Full Text] [Related]
15. [Rabeprazole induced acute interstitial nephritis].
Baudeau C; Dard S; Zylberberg H; Patey-Mariaud de Serre N
Rev Med Interne; 2008 Oct; 29(10):834-6. PubMed ID: 18395944
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
Hunfeld NG; Touw DJ; Mathot RA; Mulder PG; VAN Schaik RH; Kuipers EJ; Kooiman JC; Geus WP
Aliment Pharmacol Ther; 2010 Jan; 31(1):150-9. PubMed ID: 19785625
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence study of a fixed dose combination tablet containing rabeprazole and diclofenac sodium in healthy Indian subjects.
Mukherjee J; Das A; Chakrabarty US; Sahoo B; Sengupta P; Chatterjee B; Roy B; Pal TK
Arzneimittelforschung; 2010; 60(8):506-9. PubMed ID: 20863007
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Evaluation of Nasogastric Tube Delivery Performance of Esomeprazole Magnesium Delayed-Release Capsules.
Hoover A; Sun D; Wen H; Jiang W; Cui M; Jiang X; Keire D; Guo C
J Pharm Sci; 2017 Jul; 106(7):1859-1864. PubMed ID: 28416417
[TBL] [Abstract][Full Text] [Related]
19. Patients Should Not Swallow AcipHex Sprinkle Capsules!
Shastay A
Home Healthc Now; 2020; 38(1):52-53. PubMed ID: 31895899
[No Abstract] [Full Text] [Related]
20. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
